Our future workforce. Flemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk
|
|
|
- Hortense Mills
- 5 years ago
- Views:
Transcription
1 Our future workforce Flemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk
2 ISPE Nordic 17. Nov Who am I? Head of Quality in Novo Nordisk 48 years Danish Married 5 Children [7-19] Free time: soccer, cycling and my family Chemical Engineer 22 years with Novo Nordisk Production chemist Department Manager, Purification Plant, Diabetes API, Product Supply Vice President, Diabetes API, Product Supply Senior Vice President, Biopharm, Product Supply Senior Vice President, Corporate Quality Head of Quality
3 ISPE Nordic 17. Nov The current situation at Novo Nordisk Novo Nordisk share price development in % YTD
4 Novo Nordisk at a glance a Danish-based global healthcare company 90 years of innovation and leadership in diabetes care Haemophilia, growth disorders and obesity. PRODUCTS MARKETED IN 180 COUNTRIES DIABETES 80 DIFFERENT NATIONALITIES WORKING IN NOVO NORDISK IN DENMARK AFFILIATES IN COUNTRIES 75 R&D CENTRES IN CHINA, DENMARK, AND US ISPE Nordic 17. Nov Novo Nordisk - Corporate Presentatio n OBESITY EMPLOYS APPROXIMATELY 41,000 PEOPLE GROWTH DISORDERS $16.3 BILLION IN TOTAL REVENUE $2.1 BILLION R&D SPEND IN 2015 SUPPLIER OF MORE THAN HALF OF THE WORLD S INSULIN 26,800,000 PEOPLE USE OUR PRODUCTS HAEMOPHILIA
5 ISPE Nordic 17. Nov Global presence DENMARK GLOBAL HEADQUARTERS NORDISK AFFILIATES 75NOVO NOVO NORDISK MARKETS ITS PRODUCTS IN COUNTRIES 180WORLDWIDE REGIONAL HEADQUARTERS 5CHINA, PACIFIC, EUROPE, US AND IO STRATEGIC PRODUCTION SITES 5BRAZIL, CHINA, DENMARK, FRANCE, US R&D CENTRES 3CHINA, DENMARK, AND THE US
6 ISPE Nordic 17. Nov It is all about the patients Children should not get diabetes in the future JENNIFER ANTHONY Jennifer has type 1 diabetes and lives in India
7 ISPE Nordic 17. Nov The Novo Nordisk Way Our ambition is to strengthen our leadership in diabetes. We aspire to change possibilities in haemophilia and other serious chronic conditions. Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.
8 ISPE Nordic 17. Nov The Triple Bottom Line is how we do business Financially responsible - profitable in the long term Socially responsible - helping people live better lives Environmentally responsible - minimising negative impacts how we earn money how we spend money patients water waste employees short term profitability long term profitability communities energy CO 2
9 ISPE Nordic 17. Nov How many of you know someone with diabetes?
10 ISPE Nordic 17. Nov Diabetes type MILLION PEOPLE LIVE WITH DIABETES Type 2 diabetes develops when the beta-cells in the pancreas start to become inefficient and produce too little insulin for the body s needs. Insulin is a hormone that controls blood sugar levels. JIM SHEEDER Jim has type 2 diabetes and lives in the US
11 ISPE Nordic 17. Nov Diabetes type 1 Type 1 diabetes develops when a person s pancreas stops producing insulin altogether. Without immediate treatment, people living with type 1 diabetes can die. Children should not get diabetes in the future JENNIFER ANTHONY Jennifer has type 1 diabetes and lives in India
12 ISPE Nordic 17. Nov Is obesity a disease?
13 ISPE Nordic 17. Nov Obesity Obesity is an abnormal or excessive accumulation of fat that may impair health. 600 MILLION PEOPLE LIVE WITH OBESITY Obesity is generally defined at a population level as a BMI* of 30 or over. *Body Mass Index (BMI) is a measure of body composition. BMI is calculated by taking a person's weight and dividing by their height squared. EVE BROUTY Eve lives in the US and has a BMI of 38
14 Diabetes and Obesity is a very competitive market ISPE Nordic 17. Nov Notes: Only companies with marketed products and global presence are included Sources: Competitive Intelligence, May 2016
15 ISPE Nordic 17. Nov What does it take to develop a drug? Cost? Time?
16 10,000 IDEAS ISPE Nordic 17. Nov From idea to patient Industry estimates that out of 10,000 ideas that begin in the lab, just 10 will ever reach the stage where they are tested on people. Out of that, one may reach the market. 10 WILL BE TESTED ON PEOPLE ONE MAY REACH THE MARKET The process normally takes 10 to 15 years from initial work in the lab until a product is launched on the market.
17 ISPE Nordic 17. Nov The journey: years from idea to patient 1 in 10,000 ideas make it to market. The average estimated development costs of a final drug is around USD 1.3 billion RESEARCH DEVELOPMENT COMMERCIALISATION Phase 4 trials Reaching the market Preparing for launch Product registration Data on safety and efficacy Clinical trials Manufacturing Research Pre-project Idea
18 ISPE Nordic 17. Nov Innovation is key
19 ISPE Nordic 17. Nov Novo Nordisk has a rich pipeline DISCOVERY PRE-CLINICAL EXPLORATORY TRIALS CONFIRMATORY APPROVAL LAUNCH LAI287 PI406 Semaglutide NASH AM833 PYY 1562 G530S Concizumab sc N8-GP OI338GT Semaglutide obesity Anti-IL-21 GLP-1 T1D OG217SC Semaglutide N8-GP somapacitan Faster Aspart N9-GP Tresiba Ryzodeg Xultophy Victoza Saxenda Source: Strategic R&D, data extracted on 09 September 2016 Insulin GLP-1 analogue Obesity NAD Haemophilia Growth Hormone LAI: Long Acting Insulin T1D: Type one diabetes OG: Oral GLP-1
20 Innovation example: GLP-1/liraglutide/Victoza Engineering work is key to success ISPE Nordic 17. Nov Continuous improvements: Minimizing time used for not value adding activities Optimizing usage of purification steps Maximizing utilisation of pumps, vessels and equipment Optimizing cleaning procedures Result: Capacity optimized 250% Yield maximized with more than 50%
21 ISPE Nordic 17. Nov Innovation example: Biologics in a tablet Novo Nordisk is researching the holy grail biological medicines in a tablet. It has been pursued for a 100 years and we have failed a couple of times. Oral semaglutide is to be the first proteinbased medicine in a tablet.
22 ISPE Nordic 17. Nov Critical talent at Novo Nordisk IT/Automation Engineers Mechanical/Chemical Engineers Health Economists Medical Doctors QA/IT Specialists Biostatisticians Source: Novo Nordisk Quarterly Talent Brief, August 2016
23 ISPE Nordic 17. Nov AND. there is a global cry for engineers across industrial sectors Source: ManpowerGroup, 2015 Talent Shortage Survey
24 ISPE Nordic 17. Nov Why is it difficult to fill jobs?
25 ISPE Nordic 17. Nov TOP 5 KEY REASONS FOR DIFFICULTY FILLING JOBS 35% Lack of available applicants/no applicants 34% Lack of technical competencies ( hard skills ) 22% Lack of experiences 17% Lack of workplace competencies ( soft skills ) 13% Looking for more pay than offered Source: ManpowerGroup, 2015 Talent Shortage Survey
26 ISPE Nordic 17. Nov Does this matter at all for Novo Nordisk?
27 ISPE Nordic 17. Nov Example: The lack of engineers in Denmark Novo Nordisk site Kalundborg. Note: Civil and Diploma Engineers Source: Engineer The Future, Prognosis for lack of engineers and candidates in natural sciences, May 2015
28 ISPE Nordic 17. Nov ½ Source: Novo Nordisk Annual Report 2015
29 Ongoing expansions in Denmark ISPE Nordic 17. Nov
30 ISPE Nordic 17. Nov In the US, we are expanding our production capacity and we need engineers Diabetes API, Clayton USA
31 ISPE Nordic 17. Nov We need ISPE to
32 ISPE Nordic 17. Nov We need ISPE: Bring political attention to the need for engineers Stimulate positive public discussion around the field of engineering and Lead by example: engineers are crucial in solving global challenges in a sustainable way Share modern complexities of hiring specialists, generalists and everybody in-between Build pride within our profession
33 ISPE Nordic 17. Nov Contact: LinkedIn:
Slide 1. Investor presentation. Copenhagen 1 November 2018
Slide 1 Investor presentation Copenhagen 1 November 2018 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type 1 diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Highlights
11. December 2017 Marianne Birkeland Kjær
1 11. December 2017 Marianne Birkeland Kjær Presentation title Date 2 Agenda My Background Novo Nordisk Overview PhD and PostDoc opportunities How to apply for regular positions Novo Nordisk standard recruitment
Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
Slide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
Slide 1. Investor presentation. Meet the Management London, 9 August 2018
Slide 1 Investor presentation Meet the Management London, 9 August 2018 Manato diagnosed with type 1 diabetes Shirley Ohara, Adelia Stewart has type 2 diabetes Kanagawa, Japan New Orleans, Louisiana, US
The value of integrated reporting
The value of integrated reporting Jesper Lindhardt Director Triple Bottom Line Strategy & Performance Management Novo Nordisk at a glance Key facts A focused pharmaceutical company with leading positions
Slide 1. R&D strategy. Mads Krogsgaard Thomsen EVP and Chief Science Officer. ZIHAO LI AND HIS MOTHER BING HAN, China Zihao has haemophilia A
Slide 1 R&D strategy Mads Krogsgaard Thomsen EVP and Chief Science Officer ZIHAO LI AND HIS MOTHER BING HAN, China Zihao has haemophilia A R&D strategy Slide 2 Forward-looking statements Novo Nordisk s
Type 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
Type 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research "Type 1 diabetes market size was valued at USD 25.52 billion in 2016 and is expected to exhibit rewarding
Slide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes
Slide 1 Investor Presentaton Jefferies Global Healthcare Conference New York, 7 June 2016 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
Industrial careers. Palle Høy Jakobsen Director Head, R&D Academic Fellowships Novo Nordisk A/S
Industrial careers Palle Høy Jakobsen Director Head, R&D Academic Fellowships Novo Nordisk A/S A Mission Impossible? 10 Jan 2013 2 Career oppertunities. PRIVATE The pharmaceutical industry PUBLIC Universities
Slide 1. First six months of London 10 August Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide 1 First six months of 2017 London 10 August 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
Oral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
Slide 1. Conference call Full year 2018
Slide Conference call Full year 208 Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished
Business update InvestorDagen
Slide 1 Business update 28 November 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities
Curriculum Vitae. Jeppe Kjems. Summary
Curriculum Vitae Jeppe Kjems Position: Owner, CU-Engineering Education: ETM, Engineering Technology Management, 2000, M.Sc., Dairy Engineering, 1986 Year of birth: 1958 Languages: Danish, English, Portuguese,
NOVO NORDISK. Analyst: Recommendation: HOLD DATE: Industry: Drug manufacturers
NOVO NORDISK Analyst: Recommendation: HOLD DATE: 11.11.2015 Industry: Drug manufacturers Share price 375,00 DKK Homepage www.novonordisk.com Ticker NVO Number of shares (000) 2.563.800 Target price 406,14
Net profit increased by 1% to DKK 38.6 billion and diluted earnings per share increased by 4% to DKK
report for the period 1 January 2018 to 31 December 2018 1 February 2019 Novo Nordisk's operating profit decreased by 4% in Danish kroner and increased by 3% in local currencies in 2018 Operating profit
Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 Sales increased by 4% measured in Danish kroner
report for the period 1 January 2017 to 30 June 2017 9 August 2017 Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 Sales increased by 4% measured in Danish kroner
Financial report for the period 1 January 2017 to 30 September November Novo Nordisk A/S Investor Relations
report for the period 1 January 2017 to 30 September 2017 1 November 2017 Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 Reported sales increased by 2% to DKK 83.7
2016 EFPIA Data Collection and Reporting Experience - Novo Nordisk A/S learnings
CBI Global Transparency Reporting Congress, London 4 April 2017 1 2016 EFPIA Data Collection and Reporting Experience - Novo Nordisk A/S learnings London 4-Apr-2017 CBI Global Transparency Reporting Congress,
Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018
report for the period 1 January 2018 to 30 June 2018 8 August 2018 Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018
Slide 1. Investor presentation Full year London, 4 February Shanghai part of Cities Changing Diabetes
Slide 1 Investor presentation Full year 2015 London, 4 February 2016 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
Cardboard, injections and emotions Service design put in use
Service Design Case: Emotional Pack 15-05-2018 1 Service Design Institute Master Class 15.05.2018 Cardboard, injections and emotions Service design put in use Bo Borbye Pedersen Design Lead, Device R&D,
Strategy at Work. MedStar Health. Engaging people, improving performance
Strategy at Work MedStar Health Engaging people, improving performance About MedStar Health A $3.1 billion nonprofit health care organization formed in 1998 Headquartered in Columbia, MD Operates eight
Novo-Nordisk As (NVO-NYSE) Analyst Note
February 03, 2015 Novo-Nordisk As (NVO-NYSE) Analyst Note NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 02/10/2014 Current Price (02/02/15) $44.73 Target Price $47.00
MAGAZINE NOVO NORDISK RESEARCH CENTRE OPENS IN OXFORD PHASE 2 DATA FOR SOMAPACITAN DEMONSTRATE BIG POTENTIAL CONNECTED INSULIN PENS POISED FOR LAUNCH
MAGAZINE NO 3 218 QUARTERLY INVESTOR UPDATE NOVO NORDISK RESEARCH CENTRE OPENS IN OXFORD PHASE 2 DATA FOR SOMAPACITAN DEMONSTRATE BIG POTENTIAL CONNECTED INSULIN PENS POISED FOR LAUNCH NINE MONTHS OF SOLID
Slide 1. Investor presentation First nine months of 2018
Slide Investor presentation First nine months of Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Agenda Highlights
Slide 1. First three months of 2018 Conference call
Slide First three months of 208 Conference call Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Agenda Highlights
Investor Update May 2016
Investor Update May 2016 Novo Nordisk poised for growth through helping care for rising global diabetes epidemic On Marsico Capital Management s trip to Australia in March, Portfolio Managers Tom Marsico
Slide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
Chronic illness is a growing market for Novo Nordisk
Chronic illness is a growing market for Novo Nordisk Aslam Dalvi - Associate Portfolio Manager Denmark-based global healthcare company Novo Nordisk traces its origins to the first pioneers in insulin production
novo nordisk R&D AT A GLANCE
novo nordisk R&D AT A GLANCE LIU WEI & THOMAS JUNKER ALSTED Liu is a special technician and Thomas is an international postdoc in Research & Development in Novo Nordisk, Denmark PASSIONATE ABOUT PROTEINS
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
Slide 1. Investor presentation Full year 2018
Slide Investor presentation Full year 28 Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking statements o Nordisk s reports filed with or furnished
Research and Forecast on China Insulin Market, (Sample)
Research and Forecast on China Insulin Market, 2014-2018 (Sample) Huidian Research Publication Date: April 2014 3. Trend of China Insulin Market in 2013 3.1 Current Situation 3.1.2 Market Scale A survey
share SAXENDA LAUNCHED IN THE US FOR THE TREATMENT OF OBESITY POSITIVE TRIAL RESULTS FOR GLP-1 TABLET FIRST QUARTER: OPERATING PROFIT INCREASED BY 17%
share QUARTERLY INVESTOR UPDATE MAY 21 QUARTERLY INVESTOR UPDATE MAY 21 SAXENDA LAUNCHED IN THE US FOR THE TREATMENT OF OBESITY POSITIVE TRIAL RESULTS FOR GLP-1 TABLET FIRST QUARTER: OPERATING PROFIT INCREASED
Company presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018
Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic
China Insulin Industry Report, Jan. 2011
China Insulin Industry Report, 2010 Jan. 2011 This report analyzes the status, competition pattern and development direction of the insulin industry Focuses on the operation and development prospect of
H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review
H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
Investor conference call First quarter of 2016
Slide 1 Investor conference call First quarter of 2016 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events By Lars Rebien Sørensen, president and CEO Sales update By Lars
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
Slide 1. Jefferies 2014 Global Healthcare Conference 5-June Karsten Munk Knudsen CVP of Finance & IT at NNI
Slide 1 Jefferies 2014 Global Healthcare Conference 5-June-2014 Karsten Munk Knudsen CVP of Finance & IT at NNI Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
Vision. Mission. Hopelink s Values. Introduction. A community free of poverty
Vision A community free of poverty Mission Hopelink s mission is to promote self-sufficiency for all members of our community; we help people make lasting change. Hopelink s Values Growth and Human Potential
eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research " Projected to grow at a CAGR of around 12%, eclinical solutions market is expected to witness significant
DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC)
DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC) R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p
Slide 1. Full year London 5 February Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide 1 Full year 2017 London 5 February 2018 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
What needs to happen in England
What needs to happen in England We ve heard from over 9,000 people across the UK about what it is like to live with diabetes and their hopes and fears for the future. Over 6,000 of them live in England;
Hypodermic Needles Market Analysis, Size, Share, Growth, Industry Trends and Forecasts to Hexa Research
Hypodermic Needles Market Analysis, Size, Share, Growth, Industry Trends and Forecasts to 2024 - Hexa Research " The global hypodermic needles market was estimated at USD 2,568.7 million in 2016. The primary
The corporate responsibility for health in society
The corporate responsibility for health in society 20 May 2010 The corporate responsibility for health in society Lars Rebien Sørensen CEO & President Novo Nordisk A/S The corporate responsibility for
Investor presentation First nine months of 2015
Slide Investor presentation First nine months of 25 Mexico City part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking
Asia-Pacific Electrophysiology Market Outlook to 2020
Asia-Pacific Electrophysiology Market Outlook to 2020 Reference Code: GDMECR0114DB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...
ANNUAL REPORT novo nordisk A NEW ERA OF DIABETES TREATMENT? DEFINING TIMES FOR THE US BUSINESS
novo nordisk ANNUAL REPORT 2016 Årsrapport for 2016 for Novo Nordisk A/S for perioden 1. januar til 31. december 2016 Godkendt på generalforsamlingen 23. marts 2016 Dirigent Klaus Søgaard Novo Allé, 2880
Strategic Plan
Strategic Plan 2013-2018 Strategic Plan 2013-2018 Contents The Challenges of an Aging Population.. Baycrest: fulfilling a legacy of commitment and accomplishment Looking Ahead: dedicated to serve our local
REFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Januvia for Type 2 diabetes in the 10 major pharmaceutical markets
ph Meters Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
ph Meters Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research " The ph meters market is expected to grow at a CAGR of 3% over the forecast period from 2016 to 2024." 31 October
Mexico Ostomy Drainage Bags Market Outlook to 2020
Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...
The Dual Hormonal Artificial Pancreas in Diabetes Management. Medical Innovation Day Challenge
The Dual Hormonal Artificial Pancreas in Diabetes Management Medical Innovation Day Challenge 1 Background for the challenge A paradigm shift in treating diabetes Zealand Pharma is a Danish biotech company
Putting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
Slide 1. First nine months of London 2 November Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan
Slide 1 First nine months of 2017 London 2 November 2017 Manato Ohara, diagnosed with type 1 diabetes Kanagawa, Japan Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America
Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America Chronic Care represents more than 75% of Coloplast sales and we
Green week, CBS, 23 Sep Susanne Stormer Vice President Corporate Sustainability
Green week, CBS, 23 Sep. 2013 Susanne Stormer Vice President Corporate Sustainability 2 Let s get things straight: Definition of CSR and corporate sustainability Respect for applicable legislation, and
EU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
REFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Empagliflozin for Type 2 diabetes in the 10 major pharmaceutical
Establishing LCA in the Healthcare Sector
Establishing LCA in the Healthcare Sector Nanja Hedal Kløverpris Abstract Novo Nordisk has used Life Cycle Assessment (LCA) for many years and a few years ago the company took a major step forward and
Health for Humanity 2020 Goals 2
2017 for Humanity Report Better for Humanity 2020 s 2 At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our for Humanity 2020 s, underpinned by 16 targets, focus
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3
REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 FASIGLIFAM (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 Executive Summary Fasiglifam (TAK-875): Key Metrics in the 10 Major Pharmaceutical Markets* 2022 Market Sales US $508m 5EU $127m Japan $30m China $341m
REFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Albiglutide for Type 2 diabetes in the 10 major pharmaceutical
NEWSLETTER June Summer greetings from Follicum
NEWSLETTER June 2018 Follicum hopes that this newsletter reaches as many of the company's owners and stakeholders as possible. If you wish to follow our continued development, please register your e-mail
Slide 1. Investor presentation First half of Copenhagen, 5 August Shanghai part of Cities Changing Diabetes
Slide Investor presentation First half of 26 Copenhagen, 5 August 26 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
Metabolism and diabetes
Metabolism and diabetes Research strengths of Greater Copenhagen with investment prospects LauritzenConsulting Greater Copenhagen is home to one of the leading research clusters in the world in metabolism
Insulin Pens - Medical Devices Pipeline Assessment, 2016
Insulin Pens - Medical Devices Pipeline Assessment, 2016 Insulin Pens - Medical Devices Pipeline Assessment, 2016 Sector Publishing Intelligence Limited (SPi) has been marketing business and market research
Investor presentation First nine months of 2016
Slide Investor presentation First nine months of 26 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide 3 Forward-looking
AFFILIATE HIGHLIGHT. Getting Past the Handshake
AFFILIATE HIGHLIGHT Getting Past the Handshake How smart employers are learning that progress and innovative solutions are just some of the benefits of hiring individuals with autism. Autism Society of
Metrology in pharmaceutical production
Metrology in pharmaceutical production 22/05/2013 1 Metrology in pharmaceutical production Metrologidag 2013 Lorenzo Carli, Ph.D. lzcl@novonordisk.com Contributions from: Jan Lasson Andreasen (R&D) Kirsten
Why the Increase In Obesity
Obesity From an Economist s Perspective Eric Finkelstein, PhD, MHA RTI INTERNATIONAL The Economics of Obesity (outline) Why the Increase in Obesity Rates Adverse Health Consequences Why do (or should)
FRANKFURT SITE TOUR 2017
FRANKFURT SITE TOUR 2017 MEDIA INFORMATION FRANKFURT SITE TOUR 2017 CONTENTS FRANKFURT INSULIN CITY... 4 5 DIABETES BACKGROUNDER... 6 DIABETES STATISTICS... 7 DIABETES MEDICINES... 8 IMAGE BANK... 9 NOTES...
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
JTI Switzerland. JTI Schweiz 3
JTI Schweiz 3 Who we are 300 employees JTI has been manufacturing tobacco products in the Wiggertal area for over 45 years. The local market organization and the production facility in Dagmersellen (canton
Financial statement for January Novo Nordisk A/S Investor Relations. Novo Allé 2880 Bagsværd Denmark
statement for 2012 31 January 2013 Novo Nordisk increased operating profit by 32% in 2012 Sales growth of 18% driven by Victoza, NovoRapid and Levemir Sales increased by 18% to 78.0 billion in Danish kroner
MAGAZINE CAMILLA SYLVEST JOINS EXECUTIVE MANAGEMENT NEW INTERESTING RESULTS WITH SEMAGLUTIDE
MAGAZINE NO 3 217 QUARTERLY INVESTOR UPDATE CAMILLA SYLVEST JOINS EXECUTIVE MANAGEMENT NEW INTERESTING RESULTS WITH SEMAGLUTIDE VICTOZA APPROVED IN THE US AND THE EU AS THE ONLY GLP-1 PRODUCT TO PREVENT
Novo Nordisk increased operating profit by 15% in the first six months of 2013 Sales growth of 11% driven by Victoza, NovoRapid and Levemir
report for the period 1 January 2013 to 30 June 2013 8 August 2013 Novo Nordisk increased operating profit by 15% in the first six months of 2013 Sales growth of 11% driven by Victoza, NovoRapid and Levemir
ALK-Abelló A/S. Click View,Header and Footer to change this text to filename and department name
ALK-Abelló A/S June 25, 2008 Click View,Header and Footer to change this text to filename and department name 1 Changing the way we treat allergy Piper Jaffray 19th Annual Health Care Conference, New York
REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - Executive Summary Below table provides a summary of Belviq for obesity in the nine major pharmaceutical markets during the forecast
Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
Slide 1. Investor presentation Full year Copenhagen, 3 February Shanghai part of Cities Changing Diabetes
Slide Investor presentation Full year 205 Copenhagen, 3 February 206 Shanghai part of Cities Changing Diabetes Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook Slide
Toward a healthier 2020
Toward a healthier 2020 How citizenship and sustainability can help more people live healthier lives Photo Credit: Peace Corps We re creating a new vision of health. A vision that expands the ways we ve
Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage
Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,
A world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
This is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
What do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden
What do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden Sunil Ramkali Account Director, W Communication Agency 11 th November 2014
China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020
China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
DEMENTIA: IMPLEMENTATION REPORT AND CURRENT DEVELOPMENTS EU HEALTH
DEMENTIA: IMPLEMENTATION REPORT AND CURRENT DEVELOPMENTS EU HEALTH Brussels, 19 March 2015 Michael Hübel Programme Management and Diseases Directorate-General for Health and Food Safety European Commission
Table of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7
Solvay Media Kit Table of Contents 1. About Solvay 3 1.1. Solvay at a Glance 4 1.2. Group Portfolio 5 2. Transforming Solvay 6 2.1. Solvay s Portfolio Upgrade 7 3. Organizing for the Future 9 3.1. Why